worldwide offices | stay connected | contact | help | sitemap
Home
Products
Products home
Pharmaceuticals
Vaccines and Diagnostics
Sandoz (Generics)
Over-the-Counter
Animal Health
CIBA Vision
Diseases & Conditions
Diseases & Conditions home
Dengue
Tuberculosis
Malaria
R&D
R&D home
Drug discovery and development process
Novartis Institutes for BioMedical Research (NIBR)
Pharmaceutical Development
Novartis Biologics
Corporate Research
Research and Development locations
About Novartis
About Novartis home
Mission
Businesses
People
Corporate citizenship
Partnerships
Locations
Company history
Investors
Investors home
Financial results
Share data and analysis
Event calendar
Company information
Fixed-income securities
Shareholder information
Corporate governance
Contacts and services
Latest news
Newsroom
Newsroom home
Media releases
Multimedia content
Feature stories
Fact sheet
Novartis corporate press kit
Media library
Corporate publications
Novartis newsrooms
Media contacts
Careers
Careers home
Culture and values
Learning at Novartis
Compensation and benefits
Diversity and inclusion
Corporate Volunteerism
Careers in research and development
Associate videos
Rankings and awards
Job search
Job search - US
stay connected
contact
help
sitemap
terms of use
privacy policy
26-Feb-2010Shareholders approve all proposed resolutions of Novartis Board of Directors
22-Feb-2010Novartis oral multiple sclerosis development compound Gilenia®* (FTY720) granted US priority review status
22-Feb-2010Novartis receives FDA approval of Menveo®, a vaccine to prevent meningococcal disease
View all press releases
Sign up for email alerts
Learn more about RSS feeds and how to subscribe
English newsfeed
German newsfeed
French newsfeed
Follow Novartis on Twitter
SIX
NYSE
See stock performance
Download our latest financial reports.
Annual Report 2009
Form 20-F 2009(1.3 MB)
Visit the order and download center
Use of this website is governed by our Terms of use and Privacy policy. © Novartis AG